The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
J Qu, Q Mei, L Liu, T Cheng, P Wang… - … in medical oncology, 2021 - journals.sagepub.com
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1)
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
inhibitors is the standard therapy for the first-line or second-line treatment of patients with …
[HTML][HTML] Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of clinical and …, 2021 - ncbi.nlm.nih.gov
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri… - European Journal of …, 2020 - Elsevier
Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …
[HTML][HTML] Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score≥ 2–systematic review and meta-analysis
Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
Background Single-agent pembrolizumab represents the standard first-line option for
metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death …
metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death …
The predictive value of pretreatment lactate dehydrogenase and derived neutrophil-to-lymphocyte ratio in advanced non-small cell lung cancer patients treated with …
Q Zhang, X Gong, L Sun, L Miao, Y Zhou - Frontiers in Oncology, 2022 - frontiersin.org
Background The Lung Immune Prognostic Index (LIPI) combines the lactate dehydrogenase
(LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have …
(LDH) level and the derived neutrophil-to-lymphocyte ratio (dNLR). A lot of studies have …
Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment
Y Wang, M Yang, M Tao, P Liu, C Kong, H Li… - International …, 2021 - Elsevier
Objective Immunotherapies targeting immune checkpoints have achieved encouraging
survival benefits in patients with various solid cancers. Corticosteroids are frequently …
survival benefits in patients with various solid cancers. Corticosteroids are frequently …
[HTML][HTML] First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
F Facchinetti, M Di Maio, F Perrone… - … Lung Cancer Research, 2021 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) have become the standard of care for the
first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as …
first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as …
[HTML][HTML] Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer
G Pasello, A Pavan, I Attili, A Bortolami… - Cancer treatment …, 2020 - Elsevier
Immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1) and PD-ligand 1
(PD-L1) quickly subverted the standard of treatment in Non-Small Cell Lung Cancer …
(PD-L1) quickly subverted the standard of treatment in Non-Small Cell Lung Cancer …
Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice
D Tamura, N Jinnouchi, M Abe, D Ikarashi… - International Journal of …, 2020 - Springer
Background Prognostic outcomes and safety following treatment with pembrolizumab in
patients with advanced urothelial carcinoma (UC) have not been fully elucidated in clinical …
patients with advanced urothelial carcinoma (UC) have not been fully elucidated in clinical …